SS18L1: A Potential Drug Target and Biomarker (G26039)

Target Name: SS18L1

NCBI ID: G26039

SS18L1

SS18L1: A Potential Drug Target and Biomarker

SS18L1 (SS18-like protein 1) is a protein that has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and potential therapeutic approaches to target this protein have been proposed.

Structure and Function

SS18L1 is a 25kDa protein that is expressed in various tissues, including brain, muscle, heart, and peripheral blood. It has a molecular weight of 21.9 kDa and a calculated pI of 6.3. The protein is composed of two distinct domains: an N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal domain contains a unique structural feature, a long terminal fragment (LTF), that is responsible for the protein's stability and localization to the endoplasmic reticulum (ER) and cytoplasm. The C-terminal domain contains a basic amino acid sequence that is similar to other proteins in the superfamily of evolutionarily conserved cytoskeleton-associated proteins (SACP).

SS18L1 plays a crucial role in various cellular processes, including cell adhesion, migration, and signaling. It is involved in the regulation of cell-cell adhesion by interacting with the cytoskeleton and the cell surface. It has also been shown to play a role in cell migration, as it is involved in the regulation of cell plasticity and the ability of cells to move and change their position. In addition, SS18L1 has been shown to regulate various signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival.

Drug Targeting

SS18L1 has been identified as a potential drug target due to its unique structure and function. The N-terminal domain of SS18L1 contains a large extracellular domain (LTF) that is involved in stability and localization to the ER and cytoplasm. This makes it an attractive target for small molecules, as it can be targeted directly to this region. In addition, the C-terminal domain of SS18L1 contains a basic amino acid sequence that is similar to other proteins in the SACP family, which may make it more susceptible to small molecules that can modulate protein function.

Preclinical Studies

Preclinical studies have shown that SS18L1 is a potent drug target, with both positive and negative effects on various cellular processes. For example, studies have shown that SS18L1 can be inhibited by small molecules, including inhibitors of the TGF-β pathway, which can lead to decreased cell proliferation and survival. In addition, SS18L1 has been shown to be involved in the regulation of cell adhesion, and inhibitors of cell-cell adhesion have been shown to block the activity of SS18L1.

Biomarker Studies

Biomarker studies have also shown that SS18L1 can be used as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that SS18L1 can be used as a biomarker for cancer, as it has been shown to be involved in the regulation of cell adhesion and survival. In addition, SS18L1 has been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, as it has been shown to play a role in the regulation of neurotransmitter signaling and cell survival.

Conclusion

SS18L1 is a protein that has been identified as a potential drug target and biomarker in various diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and potential therapeutic approaches to target this protein have been proposed. Further research is needed to fully understand the role of SS18L1 in various cellular processes and its potential as a drug target and biomarker.

Protein Name: SS18L1 Subunit Of BAF Chromatin Remodeling Complex

Functions: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity)

The "SS18L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SS18L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets